RxDoctor Payments Data

Lucy Miller, MD

Nephrology · la Mesa, CANPI 1467458620

Payments from drug & device makers

$2,540in general payments, 2019–2025

Across 64 payments — averaging $39.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$559
  • Amgen$317
  • Otsuka America Pharmaceutical, Inc.$304
  • Vifor Pharma, Inc.$254
  • Calliditas Therapeutics US Inc.$185
  • Mallinckrodt Enterprises LLC$180
  • plus $740 from 11 others

What the payments were for

  • Food & beverage$2,532100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,540 in reported general payments places this provider in the 60th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$266,506
Medicare patients
416
Services billed
2,078

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan14$277,172
VelphoroSucroferric Oxyhydroxide27$72,226
Thiola EcTiopronin11$27,821
VeltassaPatiromer Calcium Sorbitex11$26,586
LokelmaSodium Zirconium Cyclosilicate42$25,919
FarxigaDapagliflozin Propanediol43$25,734
JardianceEmpagliflozin12$6,679
TradjentaLinagliptin11$6,299
Cinacalcet Hcl22$2,866
Sevelamer Carbonate21$2,186
Potassium Citrate ErPotassium Citrate17$1,484
Clonidine14$946
Bumetanide15$901
Calcitriol61$831
Tamsulosin Hcl74$766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$304$277,17214 claims
Fresenius USA Marketing, Inc.Velphoro$71$72,22627 claims
AstraZenecaLokelma, Farxiga$559$51,65385 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,341 nephrology providers in California.

Other nephrology in la Mesa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →